Telix and Varian Partner to Advance Theranostic-Driven Cancer Care
Telix Pharmaceuticals has announced a strategic clinical collaboration with Varian, a Siemens Healthineers company and a global leader in radiation oncology, aimed at developing new clinical applications that integrate Telix’s radiopharmaceutical theranostic technologies with external beam radiation therapy (EBRT). The partnership reflects a growing focus on harnessing precision imaging to enhance radiation-based cancer treatment.
EBRT is one of the most commonly used and well-established cancer treatments, suitable for a broad range of solid tumors. Delivered by radiation oncologists, it often plays a critical role throughout the cancer care continuum. Telix and Varian believe that combining EBRT with advanced molecular imaging and therapeutic radiopharmaceuticals can significantly improve patient selection, personalize treatment plans, and offer more targeted care.
The first area of clinical investigation under the collaboration focuses on PSMA-PET imaging for prostate cancer patients undergoing radiotherapy. The companies will examine how Telix’s imaging agents—Gozellix and Illuccix, both kits for preparing gallium-68 gozetotide injections—can be used to better select candidates for EBRT, tailor treatment strategies including through Varian’s Ethos adaptive radiotherapy platform, and monitor treatment response. The agreement will support a combination of company-sponsored and investigator-led clinical studies.
While prostate cancer imaging is the starting point, the collaboration is designed as a broader framework for future co-development initiatives. This includes potential applications involving other PET imaging candidates in Telix’s pipeline, such as TLX250-CDx (Zircaix) and TLX101-CDx (Pixclara), as well as future therapeutic radiopharmaceuticals. By pairing Telix’s strengths in molecular imaging and theranostics with Varian’s global leadership in EBRT technology, the companies aim to expand the role of radiation oncology in both curative and palliative treatment pathways.
Dr. Arthur Kaindl, Head of Varian, highlighted the significance of the partnership, noting that integrating precision imaging directly into radiation therapy workflows will help improve treatment accuracy and personalization. “By combining Telix’s strength in molecular imaging and radiopharmaceuticals with Varian’s leadership in radiation therapy and treatment planning, we are shaping a future of more targeted, patient-focused cancer care,” he said.
Telix CEO Dr. Christian Behrenbruch described the collaboration as a transformative step for radiation oncology. “Integrating theranostics into EBRT has the potential to improve patient outcomes,” he said. “By combining Telix’s innovation in molecular imaging with Varian’s global leadership in cancer treatment technologies, we are building alliances to explore new frontiers in personalized cancer care.”
The partnership marks a significant move toward uniting imaging-guided insights with precision radiation treatment—a development both companies believe could reshape modern oncology practice.